Skip to main content

Food Effect of KH607 in Chinese Health Participants

1
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Chengdu Kanghong Pharmaceutical Group
1
KH607Phase 13 trials
Active Trials
NCT07741240Not Yet Recruiting232Est. Dec 2027
NCT07741331Not Yet Recruiting326Est. Dec 2028
NCT07634874Not Yet Recruiting16Est. Jul 2026

Trial Timeline

Clinical trial activity over time

2026
2027
2028
Chengdu Kanghong Pharmaceutical GroupKH607
Chengdu Kanghong Pharmaceutical GroupKH607
Chengdu Kanghong Pharmaceutical GroupKH607

Clinical Trials (3)

Total enrollment: 574 patients across 3 trials

A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder

Start: Jul 2026Est. completion: Dec 2027232 patients
Phase 3Not Yet Recruiting

Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder

Start: Jul 2026Est. completion: Dec 2028326 patients
Phase 3Not Yet Recruiting

A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of KH607 in Healthy Chinese Participants

Start: Jun 2026Est. completion: Jul 202616 patients
Phase 1Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Food Effect of KH607 in Chinese Health Participants | Pipeline & Competitive Landscape | Formulate